摘要
目的观察不同剂量瑞舒伐他汀治疗颈动脉粥样硬化合并高血脂患者的疗效及安全性,并进行对照分析。方法本研究选取2008年5月～2011年5月颈动脉粥样硬化合并高血脂患者110例,随机分为瑞舒伐他汀5mg组(A组)、10mg组(B组)、20mg组(C组),均为晚餐后顿服。比较3组患者治疗前后TC、TG、HDL-C、LDL-C、颈动脉斑块面积、颈内膜-中膜厚度的变化,并统计不良反应发生情况。结果 3组患者治疗后颈动脉斑块面积、颈内膜-中膜厚度均明显减小(P<0.01);TC、TG、LDL-C指标均明显降低(P<0.01),HDL-C明显增高(P<0.01)。但总体疗效C组优于B组;B组优于A组(P<0.05或0.01)。3组患者治疗前后均未发现明显不良反应。结论瑞舒伐他汀在治疗颈动脉粥样硬化合并高血脂患者方面疗效显著,具有良好的调脂,抗感染以及抗动脉硬化作用,其疗效具有一定的剂量依赖性,本研究3种剂量治疗均未发现严重不良反应,安全性值得认可。
Objective To observe the efficacy and safety of different doses of Rosuvastatin on patients with carotid atherosclerosis combined hyperlipidemia, and to conduct the comparative analysis. Methods One hundred and ten patients with carotid atherosclerosis combined hyperlipidemia were selected from May 2008 to May 2011, and randomly divided into Rosuvastatin 5 mg group （group A）, 10 mg group （group B）, 20 mg group （group C）, which were served after dinner. TC, TG, HDL-C, LDL-C, carotid plaque area, neck intima-media thickness changes were compared between three groups before and after treatment, and the incidence of adverse reactions were observed. Results Three patients carotid plaque area and carotid intima-media thickness were significantly reduced （P 〈 0.01）; TC, TG, LDL-C were significantly lower （P 〈 0.01）, HDL-C were significantly higher （P 〈 0.01）. But the overall effect of group C was better than group B; group B was better than group A （P 〈 0.05 or 0.01）. Three groups of patients before and after treatment were not found significant adverse reactions. Conclusion Rosuvastatin in the treatment of carotid atherosclerosis in patients with combined hyperlipidemia has a significant effect, with good lipid-lowering, anti-inflammatory and anti-atherosclerosis effect, its efficacy has a dose-dependent, three doses of the study treatment find no significant adverse reactions, the safety deserves recognition.
出处
《中国当代医药》
2012年第18期69-70,72,共3页
China Modern Medicine
